Renal cell carcinoma (RCC): fatter is better? A review on the role of obesity in RCC.

immune checkpoint inhibitors obesity obesity paradox renal cell carcinoma tyrosine kinase inhibitors

Journal

Endocrine-related cancer
ISSN: 1479-6821
Titre abrégé: Endocr Relat Cancer
Pays: England
ID NLM: 9436481

Informations de publication

Date de publication:
02 06 2021
Historique:
received: 22 04 2021
accepted: 05 05 2021
pubmed: 6 5 2021
medline: 15 4 2022
entrez: 5 5 2021
Statut: epublish

Résumé

Obesity represents a well-known risk factor for renal cell carcinoma development. Several studies evaluated the relationship between obesity and outcome in patients with non-metastatic and metastatic renal cell carcinoma using different parameters such as BMI, visceral fat area and s.c. fat area. These studies suggest that obesity is associated with a better prognosis in renal cell carcinoma patients. This phenomenon is called obesity paradox and it was found in other diseases in which obesity represents an established risk factor such as heart failure, diabetes, atrial fibrillation, hypertension and coronary heart disease. The purpose of this review is to analyze the mechanisms by which obesity increases the risk of renal cell carcinoma development, to describe the evidence available to date about the link obesity-outcome and to evaluate the mechanisms to explain this apparently paradoxical relationship.

Identifiants

pubmed: 33949971
doi: 10.1530/ERC-20-0457
pii: ERC-20-0457
doi:
pii:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

R207-R216

Auteurs

Fabio Turco (F)

Department of Oncology, University of Turin, at Division of Medical Oncology, San Luigi Gonzaga Hospital, Orbassano, Turin, Italy.

Marcello Tucci (M)

Medical Oncology Department, Cardinal Massaia Hospital, Asti, Italy.

Rosario Francesco Di Stefano (RF)

Department of Oncology, University of Turin, at Division of Medical Oncology, San Luigi Gonzaga Hospital, Orbassano, Turin, Italy.

Alessandro Samuelly (A)

Department of Oncology, University of Turin, at Division of Medical Oncology, San Luigi Gonzaga Hospital, Orbassano, Turin, Italy.

Maristella Bungaro (M)

Department of Oncology, University of Turin, at Division of Medical Oncology, San Luigi Gonzaga Hospital, Orbassano, Turin, Italy.

Marco Audisio (M)

Department of Oncology, University of Turin, at Division of Medical Oncology, San Luigi Gonzaga Hospital, Orbassano, Turin, Italy.

Chiara Pisano (C)

Department of Oncology, University of Turin, at Division of Medical Oncology, San Luigi Gonzaga Hospital, Orbassano, Turin, Italy.

Massimo Di Maio (M)

Department of Oncology, University of Turin, at Division of Medical Oncology, Ordine Mauriziano Hospital, Turin, Italy.

Giorgio Vittorio Scagliotti (GV)

Department of Oncology, University of Turin, at Division of Medical Oncology, San Luigi Gonzaga Hospital, Orbassano, Turin, Italy.

Consuelo Buttigliero (C)

Department of Oncology, University of Turin, at Division of Medical Oncology, San Luigi Gonzaga Hospital, Orbassano, Turin, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH